Vafa Shahabi

2.2k total citations · 1 hit paper
27 papers, 1.8k citations indexed

About

Vafa Shahabi is a scholar working on Immunology, Oncology and Biotechnology. According to data from OpenAlex, Vafa Shahabi has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 12 papers in Oncology and 12 papers in Biotechnology. Recurrent topics in Vafa Shahabi's work include Immunotherapy and Immune Responses (11 papers), Cancer Research and Treatments (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Vafa Shahabi is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Cancer Research and Treatments (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Vafa Shahabi collaborates with scholars based in United States, Sweden and Denmark. Vafa Shahabi's co-authors include David M. Berman, Scott D. Chasalow, Lisu Wang, Maria Jure–Kunkel, Anu Wallecha, Rui‐Ru Ji, Paulo Maciag, Omid Hamid, Suresh Alaparthy and Sandra Rivera and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Vafa Shahabi

27 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An immune-active tumor microenvironment favors clinical response to ipilimumab

2011 593 citations Rui‐Ru Ji, Scott D. Chasalow et al. Cancer Immunology Immunotherapy profile →

Peers

Countries citing papers authored by Vafa Shahabi

Since Specialization

Citations

This map shows the geographic impact of Vafa Shahabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vafa Shahabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vafa Shahabi more than expected).

Fields of papers citing papers by Vafa Shahabi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vafa Shahabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vafa Shahabi. The network helps show where Vafa Shahabi may publish in the future.

Co-authorship network of co-authors of Vafa Shahabi

This figure shows the co-authorship network connecting the top 25 collaborators of Vafa Shahabi. A scholar is included among the top collaborators of Vafa Shahabi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vafa Shahabi. Vafa Shahabi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events 2013 ·Journal of Translational Medicine ·Vafa Shahabi, David M. Berman, Scott D. Chasalow, Lisu Wang, Zenta Tsuchihashi, (unknown), (unknown), Maria Jure–Kunkel, Rui‐Ru Ji	132
2	Immune-priming of the Tumor Microenvironment by Radiotherapy 2013 ·American Journal of Clinical Oncology ·Vafa Shahabi, Michael A. Postow, David Tuck, Jedd D. Wolchok	74
3	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab 2012 ·Cancer Immunology Immunotherapy ·Vafa Shahabi, Gena S. Whitney, Omid Hamid, Henrik Schmidt, Scott D. Chasalow, Suresh Alaparthy, Jeffrey R. Jackson	63
4	CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. 2012 ·Journal of Clinical Oncology ·Antoni Ribas, F. Stephen Hodi, John F. Kurland, Vafa Shahabi, Stephen Francis, Cyril Konto, Andrew K. Joe, (unknown), Jedd D. Wolchok	12
5	An immune-active tumor microenvironment favors clinical response to ipilimumab breakdown → 2011 ·Cancer Immunology Immunotherapy ·Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt, John Cogswell, Suresh Alaparthy, David M. Berman, Maria Jure–Kunkel, Nathan O. Siemers, Jeffrey R. Jackson, Vafa Shahabi	593
6	Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment 2010 ·PubMed ·Vafa Shahabi, Paulo Maciag, Sandra Rivera, Anu Wallecha	51
7	Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy 2010 ·Cancer Immunology Immunotherapy ·Laurence M. Wood, Zhen-Kun Pan, Vafa Shahabi, Yvonne Paterson	23
8	Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human 2010 ·Cancer Gene Therapy ·Vafa Shahabi, Matthew M. Seavey, Paulo Maciag, Sandra Rivera, Anu Wallecha	63
9	Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy 2010 ·Seminars in Oncology ·Axel Hoos, Ramy Ibrahim, Alan J. Korman, Kald Abdallah, David M. Berman, Vafa Shahabi, Kevin M. Chin, Renzo Canetta, Rachel Humphrey	196
10	Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression 2010 ·Journal of Immunotherapy ·Hidenobu Ishizaki, (unknown), Tumul Srivastava, Kyla Driscoll Carroll, Vafa Shahabi, Edwin R. Manuel, Don J. Diamond, Joshua D.I. Ellenhorn	25
11	A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors 2009 ·Clinical Cancer Research ·Matthew M. Seavey, Zhen-Kun Pan, Paulo Maciag, Anu Wallecha, Sandra Rivera, Yvonne Paterson, Vafa Shahabi	48
12	Chapter 1 Multiple Effector Mechanisms Induced by Recombinant Listeria monocytogenes Anticancer Immunotherapeutics 2009 ·Advances in applied microbiology ·Anu Wallecha, Kyla Driscoll Carroll, Paulo Maciag, Sandra Rivera, Vafa Shahabi, Yvonne Paterson	20
13	Development of a Listeria monocytogenes based vaccine against prostate cancer 2008 ·Cancer Immunology Immunotherapy ·Vafa Shahabi, (unknown), Anu Wallecha, Sandra Rivera, Yvonne Paterson, Paulo Maciag	79
14	Statistical evaluation for detection of peptide specific interferon-γ secreting T-cells induced by HIV vaccine determined by ELISPOT assay 2005 ·Journal of Immunological Methods ·S. Bhargava Periwal, (unknown), Vafa Shahabi, Jorge Quiroz, Khushroo E. Shroff	4
15	Recombinant *Listeria* Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7 2004 ·Cancer Research ·Duane A. Sewell, Vafa Shahabi, George R. Gunn, Zhen-Kun Pan, (unknown), Yvonne Paterson	76
16	Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes 2003 ·Vaccine ·M. Cristina Cassetti, (unknown), Vafa Shahabi, Jeffrey K. Pullen, I. Caroline Le Poole, Gretchen L. Eiben, Larry Smith, W. Martin Kast	101
17	Transport Pathways for Therapeutic Concentrations of Lithium in Rat Liver 1999 ·The Journal of Membrane Biology ·Vafa Shahabi	1
18	Palmitoylation of the rat μ opioid receptor 1998 ·FEBS Letters ·Chongguang Chen, Vafa Shahabi, Wei Xu, Lee‐Yuan Liu‐Chen	23
19	Structural basis for differential receptor binding of cholera and Escherichia coli heat‐labile toxins: influence of heterologous amino acid substitutions in the cholera B‐subunit 1997 ·Molecular Microbiology ·Malin Bäckström, Vafa Shahabi, (unknown), Susann Teneberg, Anders Kjellberg, Halina Miller‐Podraza, Jan Holmgren, Michael Lebens	27
20	Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine 1996 ·Infection and Immunity ·Michael Lebens, Vafa Shahabi, Malin Bäckström, (unknown), (unknown), Jan Holmgren	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact